{"entity":{"id":"idea-fund-protected-time-physician-scientists","kind":"idea","name":"Hospital-funded protected time for clinician-scientists, repaid by trial revenue","aka":[],"tldr":"Doctors who could turn discoveries into trials are buried in clinical work. Hospitals would guarantee them research time and recover the cost from the trials and grants they bring in.","summary":"Cancer hospitals create a protected-time scheme (for example 40% for five years) for clinician-scientists leading translational projects, funded from a revolving pool seeded by philanthropy and repaid from the indirect costs of grants and per-patient trial income those clinicians generate. Selection is by translational plan and mentorship, not by publication record. Clinician-scientists are the people who take a lab finding into a phase 1 protocol, yet their numbers are falling in most countries because clinical productivity pays and research time is the first thing cut.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (The valley of death between lab and product): Butler, Translational research: crossing the valley of death (Nature 2008)","url":"https://doi.org/10.1038/453840a"}],"tags":[],"related":["idea-fund-translational-fellowships","idea-fund-surgeon-scientist-pathway"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-translational-valley","b-workforce"],"keyPapers":["paper-butler-nature"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Clinicians with guaranteed protected time initiate at least twice as many investigator-led trials and translational grants per head as matched colleagues without protected time, and the scheme becomes cost-neutral to the hospital within five years through recovered indirect costs and trial income.","rationale":"NIH's physician-scientist workforce report documents the decline; where protected time has been funded (Howard Hughes, Burroughs Wellcome career awards, UK academic clinical lecturer posts) retention and output are markedly higher. Trial income is a real revenue line at cancer centres and can be earmarked.","test":"Two cancer centres run the scheme for five years with financial tracking and compare trial initiations and grant income of protected clinicians with a matched internal control group.","maturity":"speculative","actor":"clinic","cost":"medium","horizonYears":4},"route":"/ideas/idea-fund-protected-time-physician-scientists/","neighbours":{"idea":[{"id":"idea-fund-surgeon-scientist-pathway","kind":"idea","name":"Funded research pathways for surgeon-scientists and radiation oncologist-scientists","route":"/ideas/idea-fund-surgeon-scientist-pathway/"},{"id":"idea-fund-translational-fellowships","kind":"idea","name":"Two-year translational fellowships that pay scientists to develop their own discovery","route":"/ideas/idea-fund-translational-fellowships/"}],"bottleneck":[{"id":"b-workforce","kind":"bottleneck","name":"Not enough oncologists, nurses, pathologists, physicists","route":"/bottlenecks/b-workforce/"},{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/"}],"paper":[{"id":"paper-butler-nature","kind":"paper","name":"Translational research: crossing the valley of death","route":"/key-papers/paper-butler-nature/"}]}}